Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H28O2 |
Molecular Weight | 312.4458 |
Optical Activity | ( - ) |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]
InChI
InChIKey=WWYNJERNGUHSAO-XUDSTZEESA-N
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
Molecular Formula | C21H28O2 |
Molecular Weight | 312.4458 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021225s031lbl.pdfhttps://www.drugbank.ca/drugs/DB09389 | https://www.drugs.com/drp/norgestrel.html | https://www.ncbi.nlm.nih.gov/pubmed/8136310Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25698840
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021225s031lbl.pdfhttps://www.drugbank.ca/drugs/DB09389 | https://www.drugs.com/drp/norgestrel.html | https://www.ncbi.nlm.nih.gov/pubmed/8136310
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25698840
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active. Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy. Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3139361 |
|||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3139361 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MIRENA Approved UseMirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired. Launch Date9.7606081E11 |
|||
Primary | MIRENA Approved UseMirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired. Launch Date9.7606081E11 |
|||
Sources: https://www.drugs.com/drp/norgestrel.html |
Preventing | OVRETTE Approved UseProgestin-only oral contraceptives are indicated for the prevention of pregnancy. Launch Date1.20182399E11 |
||
Sources: https://www.drugs.com/pro/elinest.html |
Preventing | ELINEST Approved UseOral contraceptives are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Launch Date1.33289279E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30703352 |
1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
14.11 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12169384 |
0.75 mg single, oral dose: 0.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
360.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30703352 |
1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
123.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12169384 |
0.75 mg single, oral dose: 0.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30703352 |
1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
24.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12169384 |
0.75 mg single, oral dose: 0.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVONORGESTREL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 ug 1 times / day multiple, intrauterine Recommended Dose: 20 ug, 1 times / day Route: intrauterine Route: multiple Dose: 20 ug, 1 times / day Sources: Page: p.10 |
healthy, 16-45 n = 1714 Health Status: healthy Condition: Prevention of pregnancy Age Group: 16-45 Sex: F Population Size: 1714 Sources: Page: p.10 |
Disc. AE: Bleeding... AEs leading to discontinuation/dose reduction: Bleeding (1.5%) Sources: Page: p.10 |
20 ug 1 times / day multiple, intrauterine Recommended Dose: 20 ug, 1 times / day Route: intrauterine Route: multiple Dose: 20 ug, 1 times / day Sources: Page: p.2 |
healthy, 27.3 ± 5.7 n = 1700 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.3 ± 5.7 Sex: F Population Size: 1700 Sources: Page: p.2 |
Disc. AE: Menstrual irregularity, Amenorrhea... AEs leading to discontinuation/dose reduction: Menstrual irregularity (0.7%) Sources: Page: p.2Amenorrhea (0.06%) |
90 ug 1 times / day multiple, oral Recommended Dose: 90 ug, 1 times / day Route: oral Route: multiple Dose: 90 ug, 1 times / day Co-administed with:: ethinyl estradiol, p.o(20 ug; q.d; 1 year) Sources: Page: p.507 |
healthy, 27.6±6.7 n = 323 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.6±6.7 Sex: F Population Size: 323 Sources: Page: p.507 |
Disc. AE: Metrorrhagia, Bleeding vaginal... AEs leading to discontinuation/dose reduction: Metrorrhagia (8.7%) Sources: Page: p.507Bleeding vaginal (3.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bleeding | 1.5% Disc. AE |
20 ug 1 times / day multiple, intrauterine Recommended Dose: 20 ug, 1 times / day Route: intrauterine Route: multiple Dose: 20 ug, 1 times / day Sources: Page: p.10 |
healthy, 16-45 n = 1714 Health Status: healthy Condition: Prevention of pregnancy Age Group: 16-45 Sex: F Population Size: 1714 Sources: Page: p.10 |
Amenorrhea | 0.06% Disc. AE |
20 ug 1 times / day multiple, intrauterine Recommended Dose: 20 ug, 1 times / day Route: intrauterine Route: multiple Dose: 20 ug, 1 times / day Sources: Page: p.2 |
healthy, 27.3 ± 5.7 n = 1700 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.3 ± 5.7 Sex: F Population Size: 1700 Sources: Page: p.2 |
Menstrual irregularity | 0.7% Disc. AE |
20 ug 1 times / day multiple, intrauterine Recommended Dose: 20 ug, 1 times / day Route: intrauterine Route: multiple Dose: 20 ug, 1 times / day Sources: Page: p.2 |
healthy, 27.3 ± 5.7 n = 1700 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.3 ± 5.7 Sex: F Population Size: 1700 Sources: Page: p.2 |
Bleeding vaginal | 3.7% Disc. AE |
90 ug 1 times / day multiple, oral Recommended Dose: 90 ug, 1 times / day Route: oral Route: multiple Dose: 90 ug, 1 times / day Co-administed with:: ethinyl estradiol, p.o(20 ug; q.d; 1 year) Sources: Page: p.507 |
healthy, 27.6±6.7 n = 323 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.6±6.7 Sex: F Population Size: 323 Sources: Page: p.507 |
Metrorrhagia | 8.7% Disc. AE |
90 ug 1 times / day multiple, oral Recommended Dose: 90 ug, 1 times / day Route: oral Route: multiple Dose: 90 ug, 1 times / day Co-administed with:: ethinyl estradiol, p.o(20 ug; q.d; 1 year) Sources: Page: p.507 |
healthy, 27.6±6.7 n = 323 Health Status: healthy Condition: Prevention of pregnancy Age Group: 27.6±6.7 Sex: F Population Size: 323 Sources: Page: p.507 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf#page=17 Page: (ClinPharm) 17 |
likely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf#page=17 Page: (ClinPharm) 17 |
likely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf#page=17 Page: (ClinPharm) 17 |
likely | |||
major | yes (co-administration study) Comment: Concomitant administration of efavirenz (moderate CYP3A inducer) has been found to reduce plasma levels of levonorgestrel (AUC) by around 50%. Page: (ClinPharm) 16-17 |
|||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf#page=17 Page: (ClinPharm) 17 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf#page=17 Page: (ClinPharm) 17 |
unlikely |
PubMed
Title | Date | PubMed |
---|---|---|
Nomenclature of the gonane progestins. | 1999 Dec |
|
A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. | 1999 May-Jun |
|
Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. | 2000 Apr |
|
Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat and Valette. | 2001 Apr |
|
Oral contraceptives, thrombosis and haemostasis. | 2001 Apr |
|
Appeal court bans use of emergency contraceptive in Chile. | 2001 Apr 14 |
|
Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion. | 2001 Aug |
|
Over-the-counter advice for genital problems: the role of the community pharmacist. | 2001 Aug |
|
Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. | 2001 Aug |
|
The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women. | 2001 Aug |
|
The levonorgestrel intrauterine system: the benefits of reduced bleeding. | 2001 Jan |
|
Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland. | 2001 Jan |
|
The levonorgestrel intrauterine system: more than a contraceptive. | 2001 Jan |
|
Intrauterine contraception--what now and what next? | 2001 Jan |
|
Internet availability of contraceptives. | 2001 Jan |
|
Young women requesting emergency contraception are, despite contraceptive counseling, a high risk group for new unintended pregnancies. | 2001 Jul |
|
Levonorgestrel-only emergency contraception: real-world tolerance and efficacy. | 2001 Jul |
|
Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. | 2001 Jul |
|
Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. | 2001 Jul |
|
A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. | 2001 Jul |
|
Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro. | 2001 Jul 25 |
|
Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. | 2001 Jun |
|
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. | 2001 Jun |
|
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. | 2001 Jun |
|
The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. | 2001 Jun |
|
The need for more active promotion of emergency contraception. | 2001 Jun |
|
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. | 2001 Jun |
|
Treatment of menorrhagia. | 2001 Jun 9 |
|
Clinical recommendations for oxcarbazepine. | 2001 Mar |
|
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. | 2001 Mar |
|
Preferential prescribing of type of combined oral contraceptive pill by general practitioners to teenagers with acne. | 2001 Mar |
|
Practices of prescribing oral contraceptives in Poland. | 2001 Mar |
|
New IUD approved. | 2001 Mar |
|
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. | 2001 Mar |
|
Increased adhesiveness and internalization of Neisseria gonorrhoeae and changes in the expression of epithelial gonococcal receptors in the Fallopian tube of copper T and Norplant users. | 2001 Mar |
|
Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. | 2001 Mar |
|
Levonorgestrel-releasing intrauterine devices. | 2001 Mar 10 |
|
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection. | 2001 Mar 16 |
|
[After levonorgestrel, will mifepristone (RU486) be the next day-after pill?]. | 2001 Mar 31 |
|
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. | 2001 May |
|
Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. | 2001 Oct |
|
[Low-dose oral contraception and bone density]. | 2001 Sep |
|
Levonorgestrel-releasing IUD and breast cancer. | 2001 Sep |
|
Endometrial expression of glycodelin in women with levonorgestrel-releasing subdermal implants. | 2001 Sep |
Sample Use Guides
Mirena contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to half that value after 5 years. Mirena must be removed by the end of the fifth year and can be replaced at the time of removal with a new Mirena if continued contraceptive protection is desired.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26161412
5 × 10(-5) mol/L Levonorgestrel (LNG) revealed a time-dependent inhibition of cell proliferation and an increase of apoptosis in both human endometrial stromal cells (HESCs) and glandular cells (HEGCs). Furthermore, these cells demonstrated a significant Gap Junctional Intercellular Communication (GJIC) enhancement upon treatment with 5 × 10(-5) mol/L for 48 hours. The effects of LNG were most noticeable in HESCs rather than in HEGCs.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:48:28 UTC 2022
by
admin
on
Fri Dec 16 16:48:28 UTC 2022
|
Record UNII |
5W7SIA7YZW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G03AC03
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
WHO-VATC |
QG03AC03
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
NDF-RT |
N0000011301
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-VATC |
QG03AA07
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1 (ETH/LEV)
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-VATC |
QG03AB03
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-ATC |
G03AA07
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
WHO-ATC |
G03AD01
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
WHO-ATC |
G03FB09
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
NDF-RT |
N0000175830
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
LIVERTOX |
555
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
WHO-ATC |
G03FA11
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
||
|
NDF-RT |
N0000175602
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
NDF-RT |
N0000175832
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-VATC |
QG03AD01
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-VATC |
QG03FB09
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-VATC |
QG03FA11
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
||
|
WHO-ATC |
G03AB03
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID3036496
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
1362602
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | |||
|
5W7SIA7YZW
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
Intrauterine Levonorgestrel
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
3475
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
SUB08483MIG
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
13109
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | |||
|
D016912
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
212-349-8
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
744007
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | |||
|
Oral Levonorgestrel
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
M8063
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | Merck Index | ||
|
LEVONORGESTREL
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and ether R. Category: Contraceptive. Storage: Levonorgestrel should be kept in a well-closed container, protected from light.Definition: Levonorgestrel contains not less than 98.0% and not more than 102.0% of C21H28O2, calculated with reference to the dried substance. | ||
|
CHEMBL1389
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
Levonorgestrel Implant
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
5W7SIA7YZW
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
1572
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
DB00367
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
6443
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
797-63-7
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
6483
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
6373
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | RxNorm | ||
|
2881
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY | |||
|
LEVONORGESTREL
Created by
admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
|
PRIMARY | |||
|
C47585
Created by
admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
PLASMA; URINE
|
||
|
PARENT -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
impurity O at 200 nm: maximum 0.3 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|